Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.65 |
| ▸ | HRH1 | P35367 | 4/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.65 |
| ▸ | DRD3 | P35462 | 3/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.65 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.65 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.65 |
| ▸ | HTR2A | P28223 | 3/20 | 0.65 |
| ▸ | HTR2C | P28335 | 3/20 | 0.65 |
| ▸ | HTR2B | P41595 | 3/20 | 0.65 |
| ▸ | HRH2 | P25021 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cizolirtine SCHEMBL290138 | 1.00 | SLC6A2 (0.65) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| Cizolirtine SCHEMBL5186750 | 1.00 | SLC6A2 (0.65) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL4910683 | 0.92 | SLC6A2 (0.54) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL4902097 | 0.89 | SLC6A2 (0.50) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL5431109 | 0.88 | SLC6A2 (0.49) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL4907316 | 0.88 | CHRM2 (0.57) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL19471225 | 0.87 | SLC6A2 (0.48) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL4909557 | 0.86 | KDM4E (0.48) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL5184053 | 0.86 | SLC6A2 (0.48) | SLC6A2SLC6A3LMNASLC6A4CHRM2 | |
| SCHEMBL4907960 | 0.86 | LMNA (0.48) | SLC6A2SLC6A3LMNASLC6A4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-04-19 | — | — | US | claimed |
| US-20050222136-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
| EP-1024137-B1 | RESOLUTION OF AMINES | ESTEVE LABOR DR (ES) | 2003-09-24 | — | — | EP | claimed |
| EP-1029852-B1 | PROCESS FOR OBTAINING ENANTIOMERS OF CIS-OLIRTINE | ESTEVE LABOR DR (ES) | 2002-11-06 | — | — | EP | claimed |
| US-6187930-B1 | REACTING SELECTED AMINE WITH OPTICALLY ACTIVE ACID SELECTED FROM (+)-DITOLUYL-L-TARTARIC ACID AND/OR (-)-DITOLUYL-L-TARTARIC ACID IN SOLVENT TO FORM DIASTEROISOMERIC SALT, SEPARATING, ISOLATING ENANTIOMER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-02-13 | — | — | US | claimed |
| US-6118009-A | Process for obtaining enantiomers of cis-olirtine | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-09-12 | — | — | US | claimed |
| EP-1029852-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF CIS-OLIRTINE | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-08-23 | — | — | EP | claimed |
| EP-1024137-A1 | RESOLUTION OF AMINES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-08-02 | — | — | EP | claimed |
| US-20100291151-A1 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010123999-A2 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20090264388-A1 | Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells | VALORISATION RECHERCHE HSCM, LIMITED PARTNERSHIP (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264388-A1 | Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells | VALORISATION RECHERCHE HSCM, LIMITED PARTNERSHIP (CA) | 2009-10-22 | — | — | US | disclosed |
| EP-1820502-A1 | Active substance combination comprising azolylcarbinol compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007090661-A2 | ACTIVE SUBSTANCE COMBINATION COMPRISING AZOLYLCARBINOL COMPOUNDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-08-16 | — | — | WO | disclosed |
| WO-2006010627-A1 | ARYL (OR HETEROARYL) AZOLYLCARBINOLS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005097099-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222136-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | disclosed |
| EP-1029852-B1 | PROCESS FOR OBTAINING ENANTIOMERS OF CIS-OLIRTINE | ESTEVE LABOR DR (ES) | 2002-11-06 | — | — | EP | disclosed |
| US-6118009-A | Process for obtaining enantiomers of cis-olirtine | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-09-12 | — | — | US | disclosed |
| EP-1029852-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF CIS-OLIRTINE | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264388-A1 | Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells | CMA1, HRH4, MRGPRX4 | SLC6A2 3830/4885SLC6A3 4284/4885LMNA 4727/4885 |
| US-20100291151-A1 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR | TACR1, HTR3A, HTR3C | SLC6A2 379/4885SLC6A3 457/4885LMNA 3268/4885 |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | PTGS1, PTGS2, PTGES2 | SLC6A2 1741/4885SLC6A3 2198/4885LMNA 2572/4885 |
| US-20050222136-A1 | Active substance combination | PTGS1, MMP8, TACR1 | SLC6A2 690/4885SLC6A3 844/4885LMNA 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.